Please login to the form below

Not currently logged in
Email:
Password:

Kyowa Kirin

This page shows the latest Kyowa Kirin news and features for those working in and with pharma, biotech and healthcare.

First Humira biosimilars reach EU market

First Humira biosimilars reach EU market

Copycat versions of the TNF inhibitor  from Amgen, Samsung Bioepis/Biogen, Mylan/Fujifilm Kyowa Kirin, and Novartis’ Sandoz unit are starting to become available in their first EU markets now that ... Imraldi. There is no word yet on the roll-out

Latest news

  • NICE U-turn on Crystiva for rare bone disease NICE U-turn on Crystiva for rare bone disease

    Reversing its initial decision to reject the drug, NICE has issued a positive recommendation for Kyowa Kirin’s rare disease drug Crystiva, the first treatment approved to target the underlying pathophysiology ... Tom Stratford, CEO, Kyowa Kirin

  • FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo

    Becomes the first drug approved to treat Sézary syndrome. The US regulator has given a green light to Kyowa Kirin’s Poteligeo, an antibody for two rare lymphomas affecting the skin, ... Kyowa Kirin tested that hypothesis in the phase III MAVORIC study,

  • Orphan drugs dominate UK Prix Galien shortlist, medtech debuts Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

    Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).

  • NICE set to reject Kyowa Kirin’s Crysvita for XLH NICE set to reject Kyowa Kirin’s Crysvita for XLH

    Honing in on the United Kingdom however, it seems that the country's cost-effectiveness watchdog has found its next victim in the form of Japanese pharma group Kyowa Kirin, which ... This doesn’t mean to say that NICE won’t change its mind in time

  • Shire gives up on Momenta-partnered Humira biosimilar Shire gives up on Momenta-partnered Humira biosimilar

    Samsung Bioepis is in pole position in Europe having filed for approval of its SB5 biosimilar in July, while Sandoz, Merck KGaA and FujiFilm/Kyowa Hakko Kirin have candidates in phase

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    $110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.

  • Pharma deals in July 2015 Pharma deals in July 2015

    AZ originally licensed the rights to the molecule from BioWa, a subsidiary of Kyowa Hakko Kirin, in all countries except Japan and certain countries in Asia. ... Still in Japan, a week later AZ agreed a joint venture with Fujifilm Kyowa Kirin Biologics

  • Pharma deals during July 2014 Pharma deals during July 2014

    announced during July was that between AZ and Kyowa Hakko Kirin (KHK) for a co-funded phase 1/1b immuno-oncology study to evaluate two separate combinations of three immunotherapeutic antibodies

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics